NPHP1 gene mutations and deletions are the most frequent cause of nephronophthisis, which leads to unavoidable kidney failure, often by the early teens. In the U.S., nephronophthisis occurs in 1 in 922,000 live births. Of that number, 6-10% of patients will also develop retinal dystrophy, which is a blinding disease of the eye. Having both is extremely rare and falls within a category of conditions termed “diseases of no commercial interest.”
For parents, it’s a triple gut punch: Your child is sick. There’s no cure. And there’s no interest in developing one.
The NPHP1 Family Foundation is dedicated to funding the accelerated development of therapies that will preserve vision for children and adults impacted by NPHP1 retinal dystrophies.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Washington, Dc, Us
- Industry
- Non-Profit Organizations
- Website
- http://www.nphp1.org
- Keywords
- Shwachman-Diamond Syndrome Alliance.
- HQ
- Washington, DC
Nphp1 Family Foundation Questions
Nphp1 Family Foundation's website is http://www.nphp1.org
Nphp1 Family Foundation's LinkedIn profile is https://www.linkedin.com/company/nphp1-family-foundation
Nphp1 Family Foundation has
2 employees.
View email and phone details for 2
employees at Nphp1 Family Foundation.
Nphp1 Family Foundation's industry is
Non-profit Organizations
Nphp1 Family Foundation's top competitors are
Odylia Therapeutics,
Shwachman-Diamond Syndrome Alliance,
Avalonbay Communities,
Greenrich Group,
Haystack Project,
Salla Treatment And Research Foundation (Star),
From Zero Communications,
Halide,
Jacobs Family Foundation,
Viin Solutions Private Limited.
Nphp1 Family Foundation's categories are Non-profit Organizations
Nphp1 Family Foundation's founding year is 2023
